Floatz logo

Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1

Leukemia

GeoVax, Inc.vaccinePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

124 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
ASPARAGINASE
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB
Idarubicine
Affiliated Hospital of Nantong University
Phase 3BB
Daunorubicin
Richard Stone, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1 is also rated in:

COVID-19Dormant
CCC
Indicative ·
53 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →